SYK
FY2026 Q1 · Calendar Q2 2026
Stryker Corporation
A late-quarter cyber incident disrupted Stryker's manufacturing and revenue recognition, producing a Q1 2026 EPS miss of 12.8% ($2.60 vs $2.98 estimated) and a revenue miss of 5.0% ($6.02B vs $6.34B estimated). Organic sales growth slowed to 2.4%, well below the full-year target. Management maintained full-year guidance of 8%–9.5% organic growth and $14.90–$15.10 adjusted EPS, implying confidence that deferred revenue will recover in subsequent quarters. Strategic initiatives — the Amplitude Vascular acquisition, a new Ortho Tech segment, and record Mako installations — signal continued investment in growth despite the setback. The stock fell 6.5% on the print but has partially recovered, recently trading at $346.59 versus a $381.79 consensus target.
EPS surprise-12.8%
Market move-6.5%
